MétaCan
Menu
Back to cohort
Record W4386777248 · doi:10.1016/s2352-5789(23)00250-3

29 Low-grade endometrioid endometrial cancer with adnexal metastasis: possible de-escalation candidate for adjuvant therapy?

2023· article· en· W4386777248 on OpenAlexaff
Andrew Vallejo, Maximillian Klar, Marcia A. Ciccone, Jason D. Wright, Lynda D. Roman, Koji Matsuo

Bibliographic record

VenueGynecologic Oncology Reports · 2023
Typearticle
Languageen
FieldMedicine
TopicEndometrial and Cervical Cancer Treatments
Canadian institutionsColumbia College
Fundersnot available
KeywordsMedicineEndometrial cancerOncologyInternal medicineMetastasisRadiation therapyExternal beam radiotherapyCancerAdjuvant therapyHazard ratioOvarian cancerGynecologyBrachytherapy

Abstract

fetched live from OpenAlex

According to the National Comprehensive Cancer Network clinical practice guidelines, patients with stage III endometrioid endometrial cancer are recommended to receive combination therapy with systemic chemotherapy and external beam radiotherapy. Mounting translational data proposed a concept of “restricted microenvironmental compatibility” in low-grade endometrioid endometrial cancer. In this theory, low-grade endometrioid tumors are indolent and further distant metastasis beyond the ovary is biologically limited. We hypothesized that this tumor group has good oncologic outcomes even after metastasis to the ovary. The objective of current study was to examine the association between adjuvant therapy and oncologic outcomes of patients with low-grade endometrioid endometrial cancer with metastasis to the adnexa. We retrospectively queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. The study population was stage IIIA grade 1–2 endometrioid endometrial cancer with ovarian or tubal metastasis only who received adjuvant therapy from 2010–2015. Patients with uterine serosal disease, nodal involvement, distant metastasis, and secondary primary cancer were excluded. The exposure was adjuvant therapy, grouped as systemic chemotherapy without external beam radiotherapy (EBRT), EBRT alone, and combination of the two. The outcome measure was endometrial cancer-specific survival. Cox proportional hazard regression model was fitted to assess the exposure-outcome association, adjusting for patient age and tumor differentiation. A total of 245 patients were evaluated. The most frequent adjuvant therapy was systemic chemotherapy alone (46.1%), followed by combination of systemic chemotherapy and EBRT (42.0%) and EBRT alone (11.8%). The median follow-up was 6.4 (IQR 5–7.8) years. The 5-year endometrial cancer-specific survival rates were 93.3% for systemic chemotherapy alone, 92.9% for EBRT alone, and 91.0% for combination therapy (P=0.963). After controlling for patient age and tumor differentiation, combination therapy (adjusted-hazard ratio 0.83, 95% confidence interval 0.36–1.89) and EBRT alone (adjusted-hazard ratio 0.86, 95% confidence interval 0.24–3.15) were not associated with endometrial cancer-specific mortality compared to systemic chemotherapy alone. This association remained robust in sensitivity analyses for grade 1 (5-year endometrial cancer-specific survival rates for systemic chemotherapy alone, EBRT alone, and both: 95.9%, 100%, and 94.9%, respectively, P=0.618) and grade 2 (91.1%, 84.6%, and 88.6%, respectively, P=0.725) lesions. Download : Download high-res image (68KB)Download : Download full-size image These results suggest that patients with low-grade endometrioid endometrial cancer with metastases to the adnexa alone have a favorable prognosis. In this cohort combination therapy may not improve oncologic outcome compared to systemic chemotherapy alone.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.469
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.003
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.362
Teacher spread0.313 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueGynecologic Oncology ReportsSame topicEndometrial and Cervical Cancer TreatmentsFrench-language works237,207